Skip to main content

Tag: Niger


Introducing new self-care family planning methods: Lessons from DMPA-SC and the Caya diaphragm

This webinar held on February 23, 2022 was hosted by Expanding Effective Contraceptive Options (EECO) led by WCG Cares with PSI and the DMPA-SC Access Collaborative led by PATH in partnership with JSI. The discussion focused on the introduction and scale up of self-care family planning methods in sub-Saharan Africa, highlighting lessons and best practices from DMPA-SC scale-up and Caya® diaphragm pilot introductions in French-speaking West Africa. Presenters from Benin, Niger, and Senegal shared successes and challenges. This webinar was offered in French.

Institutional author(s): PATH, JSI, Population Services International (PSI), Association Béninoise pour le Marketing Social et la Communication pour la Santé, Expanding Effective Contraceptive Options
Publication date: February, 2022

DMPA-SC overbranding and overpackaging in private and social marketing sectors

The desire for private sector family planning programs to have the ability to overbrand/overpackage the Pfizer Inc. DMPA-SC product, Sayana® Press, has existed since initial product introduction planning discussions among global partners in 2008–2009. The PATH-JSI DMPA-SC Access Collaborative solicited input from the team’s regional technical advisors, country coordinators, and local partners to better understand the status of overbranding, and any related advocacy­­, in the countries where we work.

Institutional author(s): PATH, JSI
Publication date: July, 2022

DMPA-SC country data dashboard

The country dashboard is a visual presentation of key data for a select list of priority countries; it provides a snapshot of the state and stage of DMPA-SC introduction/scale-up, allowing stakeholders to assess progress, identify roadblocks, guide course corrections, and inform decisions.

Institutional author(s): PATH
Publication date: August, 2020

How to Introduce and Scale Up DMPA-SC: Practical Guidance from PATH Based on Lessons Learned During Pilot Introduction

This document was created to support ministry of health and nongovernmental partners as they develop strategies to introduce and scale up subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) to increase contraceptive options and access. Available in English and French, the publication provides practical guidance based on results, evidence, and learning from the pilot introductions of DMPA-SC in four countries in Africa.

Institutional author(s): PATH
Publication date: 2018

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC)

In collaboration with ministries of health, PATH and key partners launched the first pilot introductions of subcutaneous depot medroxyprogesterone acetate (DMPA-SC, brand name Sayana® Press) in Burkina Faso, Niger, Senegal, and Uganda from July 2014 through June 2016. While each country implemented a unique introduction strategy, all agreed to track a set of uniform indicators to chart the effect of introducing this new method across settings. Existing national health information systems (HIS) were unable to track new methods or delivery channels introduced for a pilot, thus were not a feasible source for project data. We successfully monitored the four-country pilot introductions by implementing a four-phase approach: 1) developing and defining global indicators, 2) integrating indicators into existing country data collection tools, 3) facilitating consistent reporting and data management, and 4) analyzing and interpreting data and sharing results. Project partners leveraged existing family planning registers to the extent possible, and introduced new or modified data collection and reporting tools to generate project-specific data where necessary. We routinely shared monitoring results with global and national stakeholders, informing decisions about future investments in the product and scale up of DMPA-SC nationwide. Our process and lessons learned may provide insights for countries planning to introduce DMPA-SC or other new contraceptive methods in settings where stakeholder expectations for measurable results for decision-making are high.

Institutional author(s): PATH, UNFPA
Individual author(s): Aurora Anna Stout, Siri Wood, Allen Namagembe, Alain Kaboré, Daouda Siddo, Ida Ndione
Publication date: June, 2018

Journal article Evaluation and Program Planning website

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries

PATH partnered with the United Nations Population Fund (UNFPA) and country ministries of health (MOHs) to coordinate pilot introductions of subcutaneous depot medroxyprogesterone acetate (subcutaneous DMPA or DMPA-SC, brand name Sayana Press) in Burkina Faso, Niger, Senegal, and Uganda from July 2014 through June 2016 in order to expand the range of methods available to women, particularly in remote locations. The pilot introductions aimed to answer key questions that would inform decisions about future investments in DMPA-SC and scaling up product availability and service-delivery innovations nationally. These questions included the extent to which DMPA-SC would appeal to first-time users of modern contraception, as well as adolescent girls and young women; whether DMPA-SC would add value to family planning programs or simply replace DMPA-IM or other modern methods; and the trends in injectables use when introducing DMPA-SC (or any injectable) at the community level for the first time. We implemented a multi-country monitoring system to track key indicators, including the number of doses administered by category of user (e.g., new users, by client age group) or delivery channel. Providers generally collected these data using their national programs’ standard family planning registers. Data were analyzed for cumulative information and to examine trends over time using Microsoft Power Query for Excel and Tableau. Across the 4 countries, nearly half a million DMPA-SC doses were administered and approximately 135,000 first-time users of modern contraception were reached. Furthermore, 44% of the doses administered in 3 of the countries with data were to adolescent girls and young women under age 25. Switching from DMPA-IM to DMPA-SC was not widespread, ranging from 7% in Burkina Faso to 16% in Uganda. Results from these pilot introductions demonstrate that DMPA-SC has the potential to expand community-level access to injectables, maximize task-sharing strategies, and reach young women and new acceptors of family planning. Considered within the context of each country’s setting, training approach, and introduction strategy, these results can help stakeholders in other countries make informed decisions about whether and how to include this contraceptive option in their family planning programs.

Institutional author(s): PATH, UNFPA
Individual author(s): Aurora Anna Stout, Siri Wood, George Barigye, Alain Kaboré, Daouda Siddo, Ida Ndione
Publication date: March, 2018

Journal article Journal Article Link

Monitoring the introduction of DMPA-SC

From 2014 to 2016, PATH coordinated pilot introduction of the injectable contraceptive subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) in Burkina Faso, Niger, Senegal, and Uganda. These materials feature guidance for monitoring DMPA-SC introductions, monitoring results, and lessons learned, which can help inform contraceptive introduction programming for DMPA-SC and other methods.

Institutional author(s): PATH
Publication date: March, 2018

Country stakeholder interview reports on DMPA-SC self-injection

Prior to implementing the first DMPA-SC self-injection studies in sub-Saharan Africa, PATH led in-depth interviews with key family planning stakeholders in Burkina Faso, Niger, Senegal, and Uganda in 2014 to 2016. Conducted in partnership with UNFPA in Niger and Burkina Faso, these interviews covered perceived benefits, challenges, and research needs for self-injection.

Institutional author(s): PATH
Publication date: 2017